Hi-Risk/Recurrent/Advanced PrCa Video Chat, July 7, 2025
Hi-Risk/Recurrent/Advanced PrCa Video Chat, July 7, 2025
RECORD SETTER – 58 GENTS
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Novartis, Johnson and Johnson, Myriad Genetics, Telix, Blue Earth Diagnostics and Foundation Medicine
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Editor’s Picks: Small cell morphing comes up twice in record setting group.(rd)
Topics Discussed
Hawaiian denovo Nx man finds Mack Roach; is the cancer morphing into small cell?; meta-study on early chemo not relevant if high PSA on Dx ; nevermind repeat PSMA – how about a PSA test?; another post-Pluvicto Gent whose cancer appears to morph; intraductal man is offered focal therapy – hello??; treatment success; UCSD team thinks suspicious local/distant Mx bogus – proceeds with simple RT; recurrence in Canada always poses treatment problems; zoledronic acid (Zometa) or denosumab (Xgeva) derivatives for osteoporosis?; does HT with salvage RT require abi?; Kwon’s doublet upgraded to triplet; what’s wrong with SoC options for man offered trials; another Mayo man needs GU MO Heath before proceeding.
Chat Log
Richard Fiske sent: 5:15 PM
Steven T sent: 5:18 PM Note that the NCCN requires a free account to access the professional guidelines, but not for the patient guidelines.
Julian – Houston sent: 5:39 PM Embr https://embrlabs.com/products/embr-wave
John A sent: 5:45 PM Dr Erickson not a GU specialist
eric sent: 5:46 PM eric have you gain any weight during your treatment
Eric Curtis sent: 5:50 PM Nope, I’ve lost 10 to 15 pounds in the last year.
John G sent: 6:04 PM https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2811171
Gary V Portland, Oregon sent: 6:12 PM Thanks for letting me in have to leave..
John A sent: 6:23 PM advanceduropathology.com or (516) 2807930 for Epstein
Ben Nathanson sent: 6:25 PM somatostatin
AnCan Barniskis – rick sent: 6:26 PM Zhou https://profiles.mountsinai.org/ming-zhou ming.zhou@mtsinai.org
Jeff Marchi – San Francisco sent: 6:29 PM Neuroendocrine trials From: MSKCC TargetDonc onclive ascopubs There are several ongoing clinical studies targeting DLL3 in neuroendocrine prostate cancer (NEPC): • Memorial Sloan Kettering Cancer Center (MSK) is opening a clinical trial testing a radioactive ligand that targets DLL3 in people with metastatic NEPC. Patients will first be screened for DLL3 expression and, if eligible, will receive the targeted therapy. • The SKYBRIDGE trial (NCT05652686) is a phase 1/2 study evaluating peluntamig (PT217), which targets DLL3 and CD47, in patients with DLL3-expressing neuroendocrine carcinomas, including NEPC. • A phase 1b study of tarlatamab, a DLL3-targeted bispecific T-cell engager, is ongoing in patients with metastatic NEPC, showing manageable safety and encouraging anti-tumor activity in DLL3-positive cases (NCT04702737). • Other agents like HPN328, another DLL3-targeted T-cell engager, are also being tested in neuroendocrine prostate cancer. These studies reflect a strong research focus on DLL3 as a therapeutic target for NEPC.
AnCan Barniskis – rick sent: 6:30 PM Himisha Beltran https://www.dana-farber.org/find-a-doctor/himisha-beltran/
AnCan Barniskis – rick sent: 6:34 PM Transperineal PREVENT trial https://jamanetwork.com/journals/jamaoncology/fullarticle/2823969
Alfredo in Houston sent: 6:41 PM Here is a starting point for those interested in nanoknife: https://en.wikipedia.org/wiki/Nanoknife
Peter M sent: 6:58 PM Good night gents!
Dennis Correia sent: 7:00 PM good night all
Steven T sent: 7:05 PM Thanks for your input everyone! Have a great night.
Eric Curtis sent: 7:07 PM Mahalo – time to end my participation and I appreciate everyone here who has shared their stories.
Alfredo in Houston sent: 7:08 PM I have to leave and attend to family here. Thank you and good health to everyone!
AnCan Barniskis – rick sent: 7:08 PM http://advancedprostatecancer.net/?p=4509 Xgeva vs Zometa
AnCan Barniskis – rick sent: 7:08 PM https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090685/
Alain sent: 7:16 PM Thanks guys, see you next time!
Doug D sent: 7:18 PM Thanks all. See you next time.
Wes – San Diego sent: 7:19 PM To all. Your great advice over the past 6 months helped me immensely in finding and getting great care, and a treatment plan that matched my goals.
George (Chicago) sent: 7:27 PM Thank you, gentlemen. Very helpful.
Bob Schwartz, USN, Venice FL sent: 7:35 PM Good mtg., got to go.
Thomas M sent: 7:37 PM Thank you all for your help. Thomas.
Jon McPhee Toronto sent: 7:37 PM Thanks. Goodnight.
Steve White sent: 7:44 PM Thanks so much for your help tonight. Goodnight.